C. Lebedinsky
12 Papers
135 Citations
C. Lebedinsky is an academic researcher. The author has contributed to research in topics: Trabectedin & Population. The author has an hindex of 8, co-authored 12 publications.
Chat about Author
Papers
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial
Andres Poveda,Ignace Vergote,Sergei Tjulandin,B. Kong,M. Roy,Stephen Chan,E. Filipczyk-Cisarz,Hans Hagberg,Stan B. Kaye,Nicoletta Colombo,C. Lebedinsky,Trilok V. Parekh,J. Gomez,Youn C. Park,V. Alfaro,Bradley J. Monk +15 more
TL;DR: This hypothesis-generating analysis demonstrates that superior benefits with trabectedin/PLD in terms of PFS and survival in the overall population appear particularly enhanced in patients with partially sensitive disease (PFI 6–12 months).
165
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval
Stan B. Kaye,Nicoletta Colombo,Bradley J. Monk,Sergei Tjulandin,B. Kong,M. Roy,Stephen Chan,E. Filipczyk-Cisarz,Hans Hagberg,Ignace Vergote,C. Lebedinsky,Trilok V. Parekh,P. Santabarbara,Youn C. Park,Antonio Nieto,Andres Poveda +15 more
TL;DR: Analysis of subsequent therapies and survival outcomes in the overall population and in the subsets according to platinum sensitivity support the hypothesis that the enhanced survival benefits in the partially platinum-sensitive subset might be due to an extended PFI leading to longer survival with subsequent platinum.
62
Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies
Bahram Forouzesh,Manuel Hidalgo,Quincy Siu-Chung Chu,Alain C. Mita,Monica M. Mita,Garry Schwartz,José Enrique Garzón Jimeno,J. Gomez,Vicente Alfaro,C. Lebedinsky,P. Zintl,Eric K. Rowinsky +11 more
TL;DR: The manageable toxicities at the MTDs, preliminary evidence of antitumor activity, pharmacokinetic profile, and the unique mechanistic aspects of trabectedin warrant further disease-directed evaluations on weekly schedules.
30
Trabectedin (T) in relapsed advanced ovarian cancer (ROC): A pooled analysis of three phase II studies
Scott McMeekin,J. M. Del Campo,Nicoletta Colombo,Carolyn N. Krasner,A. Roszak,Patricia S. Braly,T. E. Ciuleanu,C. Lebedinsky,M. A. Izquierdo,Cristiana Sessa +9 more
TL;DR: Trabectedin is a DNA minor groove binding drug with a distinct MoA under development in sarcoma, prostate, breast and ROC and a pooled analysis of efficacy and safety was performed.
18
Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Tr) plus pegylated liposomal doxorubicin (Tr+PLD) versus PLD alone: Results from a PPS cohort of a phase III study.
Andres Poveda,Sergei Tjulandin,B. Kong,M. Roy,Stephen Chan,E. Filipczyk-Cisarz,Hans Hagberg,C. Lebedinsky,Trilok V. Parekh,Bradley J. Monk +9 more
TL;DR: Baseline characteristics of pts with PPS were balanced and consistent with those of the overall study population, and outcomes of this nonplatinum combination on PFS, RR and OS are shown.
11